Royce & Associates LP Trims Position in Entrada Therapeutics, Inc. $TRDA

Royce & Associates LP decreased its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 28.5% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 247,147 shares of the company’s stock after selling 98,360 shares during the period. Royce & Associates LP owned 0.65% of Entrada Therapeutics worth $2,541,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. State of Wyoming increased its position in Entrada Therapeutics by 130.9% during the second quarter. State of Wyoming now owns 7,575 shares of the company’s stock worth $51,000 after purchasing an additional 4,295 shares during the last quarter. Russell Investments Group Ltd. increased its position in Entrada Therapeutics by 72.7% during the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after purchasing an additional 3,707 shares during the last quarter. AXQ Capital LP acquired a new position in Entrada Therapeutics during the third quarter worth approximately $67,000. Occudo Quantitative Strategies LP acquired a new position in Entrada Therapeutics during the second quarter worth approximately $68,000. Finally, Jain Global LLC acquired a new position in Entrada Therapeutics during the third quarter worth approximately $69,000. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Wall Street Analysts Forecast Growth

TRDA has been the subject of several research analyst reports. HC Wainwright lowered shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Oppenheimer upped their price target on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a research report on Monday, April 6th. Guggenheim raised shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Wall Street Zen lowered shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

Entrada Therapeutics Stock Up 3.7%

Entrada Therapeutics stock opened at $7.07 on Friday. Entrada Therapeutics, Inc. has a 52-week low of $4.93 and a 52-week high of $16.45. The firm has a fifty day moving average of $10.95 and a 200-day moving average of $10.85. The firm has a market capitalization of $274.46 million, a P/E ratio of -1.77 and a beta of -0.09.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.11. Entrada Therapeutics had a negative net margin of 2,895.05% and a negative return on equity of 51.22%. The company had revenue of $0.88 million during the quarter, compared to analyst estimates of $2.92 million. On average, research analysts expect that Entrada Therapeutics, Inc. will post -4.12 EPS for the current fiscal year.

Insider Buying and Selling at Entrada Therapeutics

In other news, insider Natarajan Sethuraman sold 25,907 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $15.39, for a total value of $398,708.73. Following the completion of the transaction, the insider directly owned 216,317 shares in the company, valued at approximately $3,329,118.63. This represents a 10.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernhardt G. Zeiher bought 5,000 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $5.86 per share, with a total value of $29,300.00. Following the completion of the purchase, the director directly owned 5,000 shares of the company’s stock, valued at approximately $29,300. This trade represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold 82,882 shares of company stock worth $1,169,103 over the last three months. 9.49% of the stock is currently owned by insiders.

Entrada Therapeutics Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.